Dr. Christos Fountzilas

Christos Fountzilas

MD

Specializing In:

Pancreatic Cancer Liver Cancer Colon Cancer Esophageal Cancer

Special Interests:

Personalized therapy of gastrointestinal malignancies Immunotherapy for gastrointestinal malignancies Oncolyitic viruses Drug development Biomarker identification

About Me

Biography:

Dr. Fountzilas is a board certified medical oncologist in the gastrointestinal medical oncology department at Roswell Park Comprehensive Cancer Center with a focus in pancreatic cancer. His research interests include oncolytic virotherapy, biomarker discovery, and immunotherapy for gastrointestinal cancers. His interest was sparked in gastrointestinal and clinical research during his fellowship training at the University of Texas Health Science Center at San Antonio where he designed a clinical trial involving combination immunotherapy and oncolytic viral therapy in relapsed adenocarcinoma of the pancreas. He gained further experience in clinical trial design through his participation in the American Association for Cancer Research/American Society of Clinical Oncology 2015 Methods in Clinical Cancer Research Workshop and Cancer Research Training Program from Cancer Prevention and Research Institute of Texas.


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology

Background

Education and Training:

  • 2000-2006 - MD - Aristotle University of Thessaloniki School of Medicine

Residency:

  • 2007 - 2008 - Post Graduate Internship, Athens Naval Hospital and Veterans Medical Center, Hellenic Navy, Athens, Greece
  • 2010 - 2013 - Internal Medicine, Lenox Hill Hospital, Hofstra Northwell School of Medicine, New York, New York

Fellowship:

  • 2013-2016 - Hematology and Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas

Board Certification:

  • Medical Oncology Board Certification, Greece
  • American Board of Internal Medicine-Certification in Medical Oncology
  • American Board of Internal Medicine-Certification in Hematology
  • American Board of Internal Medicine-Certification in Internal Medicine

Professional Memberships:

  • American Association for Cancer Research
  • European Society for Medical Oncology
  • American Society of Clinical Oncology
  • American Society of Hematology
  • American College of Physicians
  • Athens Medical Association

Professional Experience:

  • 2013-2016 - Hematology/Medical Oncology Fellowship, University of Texas Health Science Center at San Antonio, San Antonio, TX
  • 2010-2013 - Internal Medicine Residency, Lenox Hill Hospital, New York, NY
  • 2007-2010 - Medical Officer, Hellenic Navy, Athens, Greece

Honors & Awards

  • 2015 - 2016 - Cancer Research Training Program from Cancer Prevention and Research Institute of Texas, RP140105
  • 2015 - Harold F. and Sarah L. McDonald Scholar Award for Excellence in Oncology
  • 2015 - AACR/ASCO 2015 Methods in Clinical Cancer Research Workshop
  • 2009 - Hellenic Republic Medal for participation in international peacekeeping operations
  • 2008 - United Nations Peacekeeping Medal
  • 2006-2007 - Hellenic State Scholarship Foundation Award
  • 2005-2006 - Hellenic State Scholarship Foundation Scholarship

Publications

Full Publications list on PubMed

Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C. A phase 1 open label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. 2018 Oct 9. doi: 10.1002/cncr.31676.

Fountzilas C, Chhatrala R, Khushalani N, Tan W, LeVea C, Hutson A, Tucker C, Ma WW, Warren G, Boland P, Iyer R. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother Pharmacol. 2017 Jul 12. doi: 10.1007/s00280-017-3375-9. 

Fountzilas C, Patel S, Mahalingam D. Oncolytic Virotherapy, updates and future directions. Oncotarget. 2017 May 31. doi: 10.18632/oncotarget.18309. 
Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Coffey M, Thompson B, John Sarantopoulos J. A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2017 Apr; 79(4): 697-703. doi: 10.1007/s00280-017-3260-6. 

Fountzilas C, Stuart S, Hernandez B, Bowhay-Carnes E, Michalek J, Sarantopoulos J, Karnad A, Patel S, Weitman S, Mahalingam D. Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials? Invest New Drugs. 2017 Jan 19. doi: 10.1007/s10637-017-0425-4.

Fountzilas C, Patel S, Mahalingam D. Oncolytic Virotherapy, updates and future directions. Oncotarget. In press. 

Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Coffey M, Thompson B, John Sarantopoulos J. A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma. Cancer Chemother Pharmacol. 2017 Apr; 79(4): 697-703. doi: 10.1007/s00280-017-3260-6.

Fountzilas C, Chang K, Hernandez B, Michalek J, Crownover R, Floyd J, Mahalingam D. Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: A single institution experience. J Gastrointest Oncol. 2017 Feb;8(1): 55-63. doi: 10.21037/jgo.2016.12.11.

Fountzilas C, Stuart S, Hernandez B, Bowhay-Carnes E, Michalek J, Sarantopoulos J, Karnad A, Patel S, Weitman S, Mahalingam D. Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials? Invest New Drugs. 2017 Jan 19. doi: 10.1007/s10637-017-0425-4. Christos